FDA Approval Alert: The Need-to-Know | Axicabtagene Ciloleucel for Relapsed/Refractory Large B-cell Lymphoma Following Chemoimmunotherapy
In April 2022, axicabtagene ciloleucel was approved by the FDA for the treatment of adult patients with large B-cell lymphoma whose disease was refractory to or which relapsed within 12 months after first-line chemoimmunotherapy.
Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.
Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.